Overview

Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the ROSITEL study is to assess the effects of rosiglitazone, as compared to standard oral therapies for diabetes (metformin/sulfonylurea), on inflammatory markers and adipokine levels in diabetic patients using an angiotensin receptor blocker (ARB). We hypothesize that ARB-treated diabetic patients receiving rosiglitazone will experience greater reductions in vascular inflammation and levels of leptin and resistin, associated with increased adiponectin levels, compared to a metformin/sulfonylurea regimen, and that these benefits will result in part, from greater improvements in insulin sensitivity in the rosiglitazone group.

Phase:

N/A

Details

Lead Sponsor:

Dr. Milan Gupta

Collaborator:

GlaxoSmithKline

Treatments:

Angiotensin Receptor Antagonists
Metformin
Rosiglitazone
Telmisartan